NeuroSense Therapeutics Ltd. (NRSN) Stock Analysis & Investment Frameworks
NeuroSense Therapeutics Ltd. (NRSN) stock analysis on Invetso. Review NeuroSense Therapeutics Ltd.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
NeuroSense Therapeutics Ltd. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: IL
NeuroSense Therapeutics Ltd. Key Financial Metrics
- Market Cap: $4.63M
- Revenue: $N/A
- ROE: 723.04%
- ROIC: 628.71%
- Dividend Yield: N/A
About NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.
NeuroSense Therapeutics Ltd. Investment Frameworks
Invetso analyzes NeuroSense Therapeutics Ltd. (NRSN) across the following frameworks:
- NeuroSense Therapeutics Ltd. 10Y Growth Potential
- NeuroSense Therapeutics Ltd. Scenario Analysis
- NeuroSense Therapeutics Ltd. Risks & Opportunities
- NeuroSense Therapeutics Ltd. Economic Moat
- NeuroSense Therapeutics Ltd. Business Model
- NeuroSense Therapeutics Ltd. Management
- NeuroSense Therapeutics Ltd. SWOT Analysis
- NeuroSense Therapeutics Ltd. Porter's 5 Forces
- NeuroSense Therapeutics Ltd. PESTLE Analysis
- NeuroSense Therapeutics Ltd. ESG Analysis